Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.51 |
| ▸ | INSR | P06213 | 4/20 | 0.51 |
| ▸ | TEK | Q02763 | 4/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.51 |
| ▸ | CSF1R | P07333 | 2/20 | 0.51 |
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 5/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6313512 | 1.00 | KDR (0.51) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6313522 | 1.00 | KDR (0.51) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6319989 | 0.90 | KDR (0.63) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6401617 | 0.88 | CFTR (0.49) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL28121258 | 0.88 | KDR (0.48) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6321943 | 0.88 | CFTR (0.49) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6321949 | 0.88 | CFTR (0.49) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6399673 | 0.84 | KDR (0.45) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6401464 | 0.82 | KDR (0.54) | KDRINSRTEKPDGFRBPDGFRA | |
| SCHEMBL6394114 | 0.82 | KDR (0.57) | KDRINSRTEKPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549645-A1 | 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS | Johnson & Johnson Pharmaceutical Research & Development, Inc. (US) | 2005-07-06 | — | — | EP | claimed |
| US-20040110758-A1 | 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | claimed |
| WO-2004031184-A1 | 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, INC. (US) | 2004-04-15 | — | — | WO | claimed |
| EP-1549645-A1 | 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS | Johnson & Johnson Pharmaceutical Research & Development, Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040110758-A1 | 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | disclosed |
| WO-2004031184-A1 | 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, INC. (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110758-A1 | 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors | TIE1, KDR, FLT1 | KDR 2/4885INSR 358/4885TEK 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.